AKTX
Akari Therapeutics Plc
Halal Rating :
Last Price
$1.20
Last updated:
Market Cap
-
7D Change
-0.83%
1 Year Change
-52.0%
Company Overview
Industries
Exchange
Next Earnings Date
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. The company's lead product candidate is nomacopan, which is being developed for various conditions including pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Akari Therapeutics Plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.